127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
| Autor: | Winer, I.S., O'Cearbhaill, R.E., Bouberhan, S., Hays, J.L., Wenham, R.M., Roque, D.R., Yeku, O.O., Liu, J.F., Wang, B., Yoo, S-Y., Govindraj, S., Zhu, M., Brouwer-Visser, J., Peterman, M.J., Barnes, B., Lowy, I., Knorr, D., Uldrick, T.S., Miller, E.A. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2023 20 Supplement |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|